CELG News and Press, Celgene Corporation From 01/21/20

Chinese drug developer BeiGene (NASDAQ: BGNE)  announced on Monday strong clinical results for its cancer immunotherapy, tislelizumab. A Phase 3 trial tested the drug alongside two other chemotherapy treatments in patients with non-small cell lung cancer and successfully met its primary ...

Forty Seven Inc. (FTSV) had achieved positive results from an early-stage study in treatment-naive patients with high-risk myelodysplastic syndrome ((MDS)) and acute myeloid leukemia ((AML)). The positive results were obtained using the company's drug magrolimab in combination with Vidaza (a...

Source: abbvie.com AbbVie: Investment Thesis Investors already committed to an investment in AbbVie shares With concerns about future market directions, many prudent investors will be holding some cash in reserve. This cash will be earning little or nothing for these investors....

Quick Take Arcutis Biotherapeutics ( ARQT ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The company is advancing a pipeline of drug treatment candidates for various chronic skin conditions. ARQT is in Phase 3 trials for its...

SAN DIEGO, CA / ACCESSWIRE / January 7, 2020 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Celgene Corporation (NASDAQ:CELG) shares. Investors, who purchased shares of Celgene Corporation (NASDAQ:CELG) in 2016 or earlier and continue to hol...

Quick Take Black Diamond Therapeutics ( BDTX ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing a platform that identifies small molecule kinase inhibitors, which help to slow or stop cancer. BDTX is a ...

We've run through 10 different sectors or styles of investing in our year-end Marketplace Roundtable series. You can review the full list of roundtables at the end of this article in case you'd like to catch up on any specific angle. As we do every year, we conclude the series with the com...

Image via the Weekend Jaunts . One Of My Worst Picks From 2019 The new year is a good time to review the failures of the old one, and one of my failures last year was including Ulta Beauty ( ULTA ) among the top ten names I presented to my Marketplace subscribers in late June. Here, I'l...

Welcome to a special New Year's Day edition of Seeking Alpha's Stocks to Watch series - a preview of some key events and catalysts to look for in the new year. A podcast of Stocks to Watch is available every Sunday on Seeking Alpha , Apple Podcasts , Stitcher and Spotify (click the highl...

One of my better results in 2019 has been by buying into Celgene( CELG ) which was being acquired by ( BMY ). In that transaction, Celgene shareholders received a contingent value right or CVR which has been underestimated by the market from day one. It continues to be undervalued. The right t...